The U.S. Food and Drug Administration today approved Latuda (lurasidone HCl) tablets for the
treatment of adults with schizophrenia.
Schizophrenia affects about 1 percent of the
U.S. population, ages 18 years and older, in a given year. The most prominent symptoms include
hallucinations, delusions, disordered thinking and behavior, and suspiciousness. Hearing voices
that other people don't hear is the most common type of hallucination. These experiences can make
people with the disorder fearful and withdrawn.
Latuda is included in the atypical
antipsychotic class of drugs. All atypical antipsychotics contain a boxed warning alerting
prescribers to an increased risk of death associated with off-label use of these drugs to treat
behavioral problems in older people with dementia-related psychosis. No drug in this class is
approved to treat patients with dementia-related psychosis.
For more information,
please visit: Latuda